SciBX: Science-Business eXchange Contents: November 20 2014, Volume 7 / Issue 45

If you are unable to see the message below, click here to view.

Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Karo Bio.   TABLE OF CONTENTS November 20 2014, Volume 7 / Issue 45 Analysis Cover Story Translational Notes Tools The Distillery: Therapeutics Cancer Cardiovascular disease Infectious disease Musculoskeletal disease Neurology Renal disease The Distillery: Techniques Assays and screens Disease models Drug platforms Imaging Markers Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with PathoQuest.   Analysis Cover Story Top Tapping TOPK Benjamin Boettner doi:10.1038/scibx.2014.1308 OncoTherapy Science has a potent TOPK inhibitor in a liposomal formulation that avoids the toxicity of other cytokinesis-targeted compounds. Full Text | PDF Translational Notes Top Mixing it up at Karolinska Steve Edelson doi:10.1038/scibx.2014.1309 Karolinska's new deputy vice chancellor, Alexander von Gabain, has plans to break down silos and breed new mindsets to maximize the institute's translational potential. Full Text | PDF Tools Top Paperback diagnostics Lauren Martz doi:10.1038/scibx.2014.1310 A paper-based diagnostic using RNA switches could provide an easily distributed, rapid test for infectious diseases in point-of-care settings. Full Text | PDF HemoShear's human touch Kai-Jye Lou doi:10.1038/scibx.2014.1311 HemoShear's in vitro tumor model shows a new application for its tissue modeling technology and could open it to business from oncology companies. Full Text | PDF Distillery: Therapeutics Cancer Top DNA (cytosine-5-)-methyltransferase 1 (DNMT1) doi:10.1038/scibx.2014.1312 Cell culture studies have identified non-nucleoside selective inhibitors of DNMT1 that could help treat cancer. Full Text | PDF Fibroblast growth factor receptor (FGFR) doi:10.1038/scibx.2014.1313 In vitro studies suggest covalent, ATP-competitive FGFR inhibitors could help treat tumors with resistance mutations in the FGFR gene. Full Text | PDF Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2); K-RAS (KRAS) doi:10.1038/scibx.2014.1314 Mouse and cell culture studies suggest inhibiting NRF2 could help overcome chemotherapy resistance driven by oncogenic K-RAS. Full Text | PDF Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1; CD66a); hepatitis A virus cellular receptor 2 (HAVCR2; TIM3) doi:10.1038/scibx.2014.1315 Cell culture and mouse studies suggest co-blockade of CEACAM1 and TIM3 could help enhance antitumor immunity to treat colorectal cancer. Full Text | PDF Arginase 1 (ARG1); GABAA receptor doi:10.1038/scibx.2014.1316 In vitro and mouse studies suggest inhibiting ARG1 or agonizing the GABAA receptor could help treat neuroblastoma. Full Text | PDF Cardiovascular disease Top Interferon regulatory factor 9 (IRF9); sirtuin 1 (SIRT1) doi:10.1038/scibx.2014.1317 Mouse studies suggest inhibiting IRF9 or activating SIRT1 could help prevent arterial intimal hyperplasia caused by vascular bypass surgery. Full Text | PDF N-methylpurine-DNA glycosylase (MPG; APNG; AAG) doi:10.1038/scibx.2014.1318 Mouse studies suggest inhibiting DNA base excision repair initiated by AAG could help prevent ischemia/reperfusion injury. Full Text | PDF Stem cell factor (SCF; c-Kit ligand; KITLG) doi:10.1038/scibx.2014.1319 Porcine studies suggest SCF gene therapy could help treat MI. Full Text | PDF Infectious disease Top DNA gyrase subunit B (gyrB); topoisomerase IV Par E subunit (parE) doi:10.1038/scibx.2014.1320 Rodent and in vitro studies have identified an aminobenzimidazole urea inhibitor of bacterial gyrB and parE that could help treat bacterial infections. Full Text | PDF Endothelial cell nitric oxide synthase 3 (NOS3; eNOS) doi:10.1038/scibx.2014.1321 Mouse studies suggest agonizing NOS3 could help treat bacterial pneumonia. Full Text | PDF Musculoskeletal disease Top Latent transforming growth factor-β binding protein 4 (LTBP4) doi:10.1038/scibx.2014.1322 Mouse studies suggest inhibiting cleavage of LTBP4 could help treat muscular dystrophies. Full Text | PDF Neurology Top Adducin 1 (ADD1); ATPase Na+/K+ transporting α2 polypeptide (ATP1A2) doi:10.1038/scibx.2014.1323 In vitro and mouse studies suggest inhibiting ADD1 or ATP1A2 could help treat ALS. Full Text | PDF MAP kinase kinase kinase 12 (MAP3K12; DLK) doi:10.1038/scibx.2014.1324 In vitro and mouse studies identified DLK inhibitors that could help treat neurodegenerative diseases. Full Text | PDF Dopamine D3 receptor; serotonin (5-HT1A) receptor; serotonin (5-HT2A) receptor doi:10.1038/scibx.2014.1325 Mouse studies have identified new trifunctional arylpiperazines that could be useful as antipsychotics. Full Text | PDF Renal disease Top Transient receptor potential cation channel subfamily M member 2 (TRPM2); Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) (RAC1) doi:10.1038/scibx.2014.1326 Mouse studies suggest inhibiting TRPM2 or RAC1 could help treat ischemic kidney injury. Full Text | PDF Distillery: Techniques Assays and screens Top Paper-based diagnostics using synthetic gene networks doi:10.1038/scibx.2014.1327 Cell-free synthetic gene networks embedded in paper discs could be used to develop rapid, point-of-care diagnostics. Full Text | PDF Disease models Top Bioengineered, implantable scaffolds that recapitulate the human metastatic bone marrow microenvironment doi:10.1038/scibx.2014.1328 Bioengineered, implantable hydrogel scaffolds that mimic the human metastatic bone marrow microenvironment could help identify new targets and compounds to prevent cancer metastasis to the bone. Full Text | PDF Drug platforms Top Direct reprogramming of human fibroblasts to striatal medium spiny neurons (MSNs) doi:10.1038/scibx.2014.1329 Direct reprogramming of human fibroblasts to human striatal neurons could help generate new cellular therapies and models of neurological disease. Full Text | PDF Exogenous lysyl oxidase (LOX) treatment to enhance tensile properties in musculoskeletal grafts doi:10.1038/scibx.2014.1330 In vitro and in vivo studies suggest LOX could help enhance the function and durability of musculoskeletal grafts by improving their tensile properties. Full Text | PDF Liposomes with absorption enhancers to improve oral bioavailability doi:10.1038/scibx.2014.1331 Ex vivo and in vivo studies suggest chemically stabilized liposomes containing absorption enhancers could be useful for delivering drugs across the intestinal mucosal surface. Full Text | PDF Synthetic, universal reversal agent for heparin anticoagulants doi:10.1038/scibx.2014.1332 Synthetic, universal heparin reversal agents could help reduce bleeding complications in patients who use the drug. Full Text | PDF Imaging Top Diagnosing and monitoring treatment response of Enterobacteriaceae infections with 2-[18F]-fluorodeoxysorbitol (18F-FDS) PET imaging doi:10.1038/scibx.2014.1333 A sorbitol-based PET imaging agent could help detect and monitor treatment responses in Enterobacteriaceae infections. Full Text | PDF Fluorescently labeled anti-CD47 antibody for bladder cancer diagnosis doi:10.1038/scibx.2014.1334 Fluorescently tagged anti-CD47 antibodies could help diagnose bladder cancer. Full Text | PDF Tumor-penetrant heat shock protein 70 (Hsp70)-targeting peptide for near-infrared fluorescent (NIR) tumor imaging doi:10.1038/scibx.2014.1335 An Hsp70-targeting peptide could be useful for imaging a broad range of tumor types. Full Text | PDF Markers Top SNPs near the gene encoding estrogen receptor-α for predicting breast cancer risk in Latina women doi:10.1038/scibx.2014.1336 Genetic variants near the gene encoding estrogen receptor-α could help predict breast cancer risk in Latina women. Full Text | PDF Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.